Insmed Incorporated (NASDAQ:INSM) CEO Sells $391,248.00 in Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 5,472 shares of Insmed stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $71.50, for a total value of $391,248.00. Following the completion of the sale, the chief executive officer now owns 308,758 shares of the company's stock, valued at $22,076,197. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

William Lewis also recently made the following trade(s):

• On Monday, June 2nd, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $71.31, for a total transaction of $487,047.30.
• On Tuesday, May 20th, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $67.72, for a total transaction of $462,527.60.
• On Tuesday, May 20th, William Lewis sold 21,057 shares of Insmed stock. The shares were sold at an average price of $67.65, for a total transaction of $1,424,506.05.
• On Wednesday, May 14th, William Lewis sold 3,771 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total transaction of $247,415.31.
• On Tuesday, May 13th, William Lewis sold 17,442 shares of Insmed stock. The stock was sold at an average price of $66.97, for a total transaction of $1,168,090.74.
• On Thursday, May 1st, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $72.57, for a total value of $495,653.10.
• On Tuesday, April 15th, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $70.16, for a total value of $479,192.80.
• On Monday, March 17th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.03, for a total value of $1,444,312.50.

Insmed Stock Performance

NASDAQ INSM traded up $0.88 on Friday, hitting $73.62. 1,558,246 shares of the company traded hands, compared to its average volume of 2,072,473. The company has a market capitalization of $13.41 billion, a price-to-earnings ratio of -13.17 and a beta of 0.80. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The business's 50 day moving average price is $69.28 and its 200-day moving average price is $73.04. Insmed Incorporated has a 52-week low of $55.74 and a 52-week high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Insmed's revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter last year, the firm posted ($1.06) earnings per share. Equities analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on INSM shares. UBS Group dropped their price target on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Stifel Nicolaus dropped their price target on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. Truist Financial raised their price target on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Royal Bank of Canada restated an "outperform" rating and issued a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th. Finally, JPMorgan Chase & Co. raised their price target on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $96.73.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Insmed by 0.3% during the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock valued at $1,393,675,000 after acquiring an additional 49,149 shares during the period. Darwin Global Management Ltd. raised its holdings in Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after acquiring an additional 2,463,261 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Insmed by 1.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock valued at $985,938,000 after acquiring an additional 219,131 shares during the period. Capital International Investors raised its holdings in Insmed by 9.1% during the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after acquiring an additional 593,206 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Insmed by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock valued at $282,243,000 after acquiring an additional 273,759 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.